Related Experiment Videos

Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk

John E Gerich1

  • 1General Clinical Research Center, University of Rochester, 601 Elmwood Avenue, Box MED/CRC, Rochester, NY 14642, USA. johngerich@compuserve.com

The Diabetes Educator
|July 29, 2006
PubMed

Insights

Diabetes patients face high cardiovascular disease risk. Controlling postprandial hyperglycemia, or high blood sugar after meals, is crucial for reducing this risk, even with normal fasting glucose levels.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Syndrome

Background:

  • Cardiovascular disease (CVD) is the primary cause of death in diabetic patients.
  • Diabetes is now considered a CVD risk factor equivalent to hyperlipidemia, hypertension, and smoking.
  • Glycemic control, indicated by HbA1c levels, is essential for managing diabetes and its complications.

Observation:

  • Recent research highlights postprandial hyperglycemia as a greater CVD risk than elevated fasting plasma glucose.
  • Clinicians must recognize that elevated HbA1c can result from both fasting and postprandial hyperglycemia.
  • This is critical for patients with suboptimal HbA1c despite normal fasting glucose readings.

Findings:

  • Postprandial hyperglycemia significantly contributes to cardiovascular disease risk in diabetic individuals.
  • Elevated blood glucose levels after meals are an independent risk factor for CVD.
  • Targeting postprandial glucose is essential for comprehensive diabetes management and CVD prevention.

Implications:

  • Clinicians should consider postprandial glucose monitoring and management strategies for diabetic patients.
  • Controlling postprandial hyperglycemia may reduce the incidence of cardiovascular events in diabetes.
  • Patient education on self-monitoring and managing postprandial glucose levels is vital for improving outcomes.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...